Long-term treatment of patient with metastatic melanoma of the trunk

被引：0
|
作者：
Kempa-Kaminska, Natasza [1 ]
机构：
[1] Dolnoslaskie Ctr Onkol Wroclawiu, Oddzial Onkol Klin, Pl Hirszfelda 12, PL-53413 Wroclaw, Poland
来源：
ONCOLOGY IN CLINICAL PRACTICE | 2018年 / 14卷
关键词：
immunotherapy; melanoma; vemurafenib; hepatotoxicity;
D O I：
10.5603/OCP.2018.0063
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Currently there has been a huge development in melanoma therapy. There are drugs with high efficacy, but also with a completely new toxicity profile. Below is a case report of a patient treated for metastatic melanoma of the body. Treatment included vemurafenib and immunotherapy in the form of pembrolizumab, a monoclonal antibody blocking PD-1 receptor. Among toxicity, dermatological effects of vemurafenib treatment and hepatotoxicity during immunotherapy were observed mainly in case of treatment with vemurafenib. The applied treatment allowed for several years of survival of the patient in good general condition.
引用
收藏
页码：A19 / A22
页数：4
相关论文
共 50 条
  • [11] Swinging for the Fences: Long-Term Survival With Ipilimumab in Metastatic Melanoma
    Gibney, Geoffrey T.
    Atkins, Michael B.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (17) : 1873 - U27
  • [12] Clinical determinants of long-term survival in metastatic uveal melanoma
    Koch, Elias A. T.
    Petzold, Anne
    Wessely, Anja
    Dippel, Edgar
    Erdmann, Michael
    Heinzerling, Lucie
    Hohberger, Bettina
    Knorr, Harald
    Leiter, Ulrike
    Meier, Friedegund
    Mohr, Peter
    Rahimi, Farnaz
    Schell, Beatrice
    Schlaak, Max
    Terheyden, Patrick
    Schuler-Thurner, Beatrice
    Ugurel, Selma
    Utikal, Jochen
    Vera, Julio
    Weichenthal, Michael
    Ziller, Fabian
    Berking, Carola
    Heppt, Markus, V
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (06) : 1467 - 1477
  • [13] LONG-TERM RESPONSE TO CHEMOTHERAPY IN PATIENTS WITH VISCERAL METASTATIC MELANOMA
    COATES, AS
    SEGELOV, E
    ANNALS OF ONCOLOGY, 1994, 5 (03) : 249 - 251
  • [14] Long-term effects of BRAF inhibitors in melanoma treatment: friend or foe?
    Sloot, Sarah
    Fedorenko, Inna V.
    Smalley, Keiran S. M.
    Gibney, Geoffrey T.
    EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (05) : 589 - 592
  • [15] Melanoma, a new risk for long-term rituximab treatment?
    Chiffoleau, A.
    Peuvrel, L.
    Quereux, G.
    Brocard, A.
    Saint Jean, M.
    Batz, A.
    Dreno, B.
    Jolliet, P.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2013, 27 : 121 - 121
  • [16] Pulmonary Sarcoid-like Granulomatosis after Multiple Vaccinations of a Long-term Surviving Patient with Metastatic Melanoma
    Bordry, Natacha
    Costa-Nunes, Carla-Marisa
    Cagnon, Laurene
    Gannon, Philippe O.
    Abed-Maillard, Samia
    Baumgaertner, Petra
    Murray, Timothy
    Letovanec, Igor
    Lazor, Romain
    Bouchaab, Hasna
    Rufer, Nathalie
    Romano, Emanuela
    Michielin, Olivier
    Speiser, Daniel E.
    CANCER IMMUNOLOGY RESEARCH, 2014, 2 (12) : 1148 - 1153
  • [17] Resistance surveillance in a BRAF mutant melanoma patient on long-term BRAF-inhibitor treatment
    Mak, Gabriel
    Arkenau, Hendrik-Tobias
    Chin, Melvin
    MELANOMA RESEARCH, 2014, 24 (04) : 408 - 412
  • [18] A response to the ipilimumab treatment of a patient with a diagnosis of metastatic melanoma
    Pekala, Anika
    Ulanska, Malgorzata
    Blasinska-Morawiec, Maria
    ONCOLOGY IN CLINICAL PRACTICE, 2015, 11 : H1 - H6
  • [19] Treatment of Metastatic Melanoma in the Elderly
    Seedor, Rino S.
    Orloff, Marlana
    CURRENT ONCOLOGY REPORTS, 2022, 24 (07) : 825 - 833
  • [20] Long Term Administration of Nivolumab for Metastatic Melanoma: A Case Report
    Oprea, Adela-Raluca
    Benas, Arnaud
    Havasi, Andrei
    Gorzo, Alecsandra
    Spinu, Stefan
    Sur, Daniel
    Burz, Claudia
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (06)
12345